317 related articles for article (PubMed ID: 10202280)
61. Biological characterisation of superficial bladder cancer by bivariate cytokeratin 7/DNA analysis, flow cytometric assessment of MIB- 1, and an immunohistochemical study.
Leonardi E; Dalla Palma P; Reich A; Caffo O; Luciani L
Anal Cell Pathol; 2000; 21(1):21-33. PubMed ID: 11254222
[TBL] [Abstract][Full Text] [Related]
62. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme.
Stark AM; Hugo HH; Witzel P; Mihajlovic Z; Mehdorn HM
Zentralbl Neurochir; 2003; 64(1):30-6. PubMed ID: 12582944
[TBL] [Abstract][Full Text] [Related]
63. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
64. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
65. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
66. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Droller MJ
J Urol; 2001 May; 165(5):1811-2. PubMed ID: 11345951
[No Abstract] [Full Text] [Related]
67. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
68. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
69. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.
Sanchez E; Chacon I; Plaza MM; Muñoz E; Cruz MA; Martinez B; Lopez L; Martinez-Montero JC; Orradre JL; Saez AI; Garcia JF; Piris MA
J Clin Oncol; 1998 May; 16(5):1931-9. PubMed ID: 9586912
[TBL] [Abstract][Full Text] [Related]
70. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation.
Rödel C; Grabenbauer GG; Rödel F; Birkenhake S; Kühn R; Martus P; Zörcher T; Fürsich D; Papadopoulos T; Dunst J; Schrott KM; Sauer R
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1213-21. PubMed ID: 10725634
[TBL] [Abstract][Full Text] [Related]
71. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
[TBL] [Abstract][Full Text] [Related]
72. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
[TBL] [Abstract][Full Text] [Related]
73. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance.
Baretton GB; Diebold J; Christoforis G; Vogt M; Müller C; Dopfer K; Schneiderbanger K; Schmidt M; Löhrs U
Cancer; 1996 Jan; 77(2):255-64. PubMed ID: 8625232
[TBL] [Abstract][Full Text] [Related]
74. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
Santini D; Tonini G; Vecchio FM; Borzomati D; Vincenzi B; Valeri S; Antinori A; Castri F; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
J Clin Pathol; 2005 Feb; 58(2):159-65. PubMed ID: 15677536
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
[TBL] [Abstract][Full Text] [Related]
76. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
77. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
78. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
[TBL] [Abstract][Full Text] [Related]
79. Histopathological analysis of apoptosis, and expression of p53, bcl-2, bax, and Ki-67 in laryngeal squamous cell carcinomas and dysplasia.
Izawa H; Yonemitsu N; Shin T; Sugihara H
Auris Nasus Larynx; 1999 Jul; 26(3):317-30. PubMed ID: 10419041
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.
Souza PE; Mesquita RA; Gomez RS
Oral Dis; 2000 Jan; 6(1):35-9. PubMed ID: 10673786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
